- Home
- ACI vs NBIX Comparison
ACI vs NBIX Comparison
Compare ACI & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACI
- NBIX
- Stock Information
- Founded
- ACI 1860
- NBIX 1992
- Country
- ACI United States
- NBIX United States
- Employees
- ACI N/A
- NBIX N/A
- Industry
- ACI Food Chains
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACI Consumer Staples
- NBIX Health Care
- Exchange
- ACI Nasdaq
- NBIX Nasdaq
- Market Cap
- ACI 12.2B
- NBIX 11.0B
- IPO Year
- ACI 2020
- NBIX 1996
- Fundamental
- Price
- ACI $22.91
- NBIX $102.88
- Analyst Decision
- ACI Buy
- NBIX Buy
- Analyst Count
- ACI 12
- NBIX 21
- Target Price
- ACI $23.85
- NBIX $166.75
- AVG Volume (30 Days)
- ACI 8.4M
- NBIX 1.2M
- Earning Date
- ACI 04-15-2025
- NBIX 04-30-2025
- Dividend Yield
- ACI 2.62%
- NBIX N/A
- EPS Growth
- ACI N/A
- NBIX 33.20
- EPS
- ACI 1.78
- NBIX 3.29
- Revenue
- ACI $79,930,900,000.00
- NBIX $2,355,300,000.00
- Revenue This Year
- ACI $2.35
- NBIX $15.48
- Revenue Next Year
- ACI $2.44
- NBIX $16.18
- P/E Ratio
- ACI $12.87
- NBIX $31.27
- Revenue Growth
- ACI 0.97
- NBIX 24.81
- 52 Week Low
- ACI $17.00
- NBIX $102.54
- 52 Week High
- ACI $23.20
- NBIX $157.98
- Technical
- Relative Strength Index (RSI)
- ACI 68.92
- NBIX 30.07
- Support Level
- ACI $20.66
- NBIX $113.05
- Resistance Level
- ACI $22.05
- NBIX $112.74
- Average True Range (ATR)
- ACI 0.48
- NBIX 2.78
- MACD
- ACI 0.14
- NBIX -0.11
- Stochastic Oscillator
- ACI 88.58
- NBIX 2.34
About ACI Albertsons Companies Inc.
Albertsons is the second largest supermarket operator in the United States with more than 2,200 stores across a variety of banners. About 80% of the firm's sales stem from non-perishable and fresh food, of which 25% comes from its portfolio of private brands. The company operates fuel centers and pharmacies at about 20% and 75% of its store locations, respectively. Albertsons went public in 2020 following years of ownership under private equity firm Cerberus Capital Management, which still owns about a fourth of outstanding shares.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.